Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

F.E. Karet; Claire Dickerson; J. Brown; M.J. Brown

doi:10.1016/S0140-6736(94)90752-8

Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

F.E. Karet, Claire Dickerson, J. Brown, M.J. Brown

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.

Original language	English
Pages (from-to)	1263-1265
Journal	Lancet
Volume	344
Issue number	8932
DOIs	https://doi.org/10.1016/S0140-6736(94)90752-8
Publication status	Published - 1994

Access to Document

10.1016/S0140-6736(94)90752-8

Cite this

@article{7ae1886eb46441399faa43d61d726ea6,

title = "Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure",

abstract = "The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.",

author = "F.E. Karet and Claire Dickerson and J. Brown and M.J. Brown",

note = "Original article can be found at: http://www.sciencedirect.com/science/journal/01406736 Copyright Elsevier Ltd. [Full text of this article is not available in the UHRA]",

year = "1994",

doi = "10.1016/S0140-6736(94)90752-8",

language = "English",

volume = "344",

pages = "1263--1265",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8932",

}

TY - JOUR

T1 - Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

AU - Karet, F.E.

AU - Dickerson, Claire

AU - Brown, J.

AU - Brown, M.J.

N1 - Original article can be found at: http://www.sciencedirect.com/science/journal/01406736 Copyright Elsevier Ltd. [Full text of this article is not available in the UHRA]

PY - 1994

Y1 - 1994

N2 - The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.

AB - The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.

U2 - 10.1016/S0140-6736(94)90752-8

DO - 10.1016/S0140-6736(94)90752-8

M3 - Article

VL - 344

SP - 1263

EP - 1265

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8932

ER -

Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

Abstract

Access to Document

Fingerprint

Cite this